News In Brief

Edwards Lifesciences Corp. expands its hemodynamic monitoring product offerings by acquiring privately held Dutch firm BMEYE BV for $42 million on Oct. 10. The deal includes BMEYE’s noninvasive Nexfin and ccNexfin monitoring systems. Approved for sale in the U.S. and Europe, the devices employ a noninvasive finger cuff to measure continuous, real-time information on cardiac output, blood pressure, fluid responsiveness and other hemodynamic parameters. The noninvasive devices complement Edwards’ existing portfolio of minimally invasive monitoring products, including its FloTrac sensors and PreSep and PediaSat oximetry catheters. The BMEYE devices “will provide clinicians with critical, comprehensive hemodynamic monitoring information for a broader range of patients,” said Carlyn Solomon, Edwards’ corporate VP, critical care and vascular. Edwards notes it plans to further develop BMEYE’s technology, which has primarily been used by clinicians outside the hospital, and integrate it into its EV1000 monitoring platform for use in the acute care setting in hospitals. The firm expects the earnings impact from the transaction to be immaterial in 2012, and slightly dilutive in 2013.

Preliminary third quarter revenues released by Edwards Lifesciences Corp. Oct. 8 were short of company estimates primarily due to sales of Sapien transcatheter heart valves that were “below expectations,” according...